Tafinlar Pediatric Dispersible Tablets 10mg

Tafinlar (dabrafenib mesylate) pediatric dispersible tablets, 10mg (YJ code: 4291046X1027, standard: 10mg 1 tablet), manufactured by Novartis Pharma, are a kinase inhibitor used for children aged 1 year and older, weighing at least 8 kg, to treat specific types of glioma with a BRAF V600 gene mutation. It is also indicated for specific types of melanoma, non-small cell lung cancer, and anaplastic thyroid cancer with a BRAF V600 gene mutation.